Last 12 months
Inside the activity.
11 purchase rows · 0 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 0 |
| Dec 2025 | 4 | 0 |
| Jan 2026 | 0 | 0 |
| Feb 2026 | 0 | 0 |
| Mar 2026 | 0 | 0 |
| Apr 2026 | 0 | 0 |
| May 2026 | 2 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 5 | 0 |
| Sep 2026 | 0 | 0 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| June 03, 2019 Filed Jun 5, 2019 20:37 UTC |
GARCIA ART ADirector
|
GrantCommon Stock | 2,819 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000337 · edgar.xml · nonDerivative · entry 1 GARCIA ART A · CIK 0001183585 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,819 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| June 03, 2019 Filed Jun 5, 2019 20:34 UTC |
Meer James MChief Accounting Officer
|
GrantCommon Stock | 475 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000335 · edgar.xml · nonDerivative · entry 1 Meer James M · CIK 0001754243 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,712 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on June 3, 2019, one-half vesting on June 3, 2020, and the remaining vesting on June 3, 2021. Read SEC document |
| May 13, 2019 Filed May 15, 2019 21:43 UTC |
BILBREY JOHN PDirector
|
PurchaseCommon Stock | 7,750 | $32.39 | $251,022.50 |
DisclosureSEC source: 0000950138-19-000302 · edgar.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Revocable Trust Disclosed balance after: 7,750 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $32.24 to $32.47, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 22, 2019 Filed Aug 26, 2019 11:41 UTC |
Harrington Michael JDirector
|
PurchaseCommon Stock | 3,500 | $26.75 | $93,607.50 |
DisclosureSEC source: 0000950138-19-000468 · edgar.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,283 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $26.74 to $26.76, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:39 UTC |
Kochevar Deborah TurnerDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000248 · edgar.xml · nonDerivative · entry 1 Kochevar Deborah Turner · CIK 0001448579 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,783 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:43 UTC |
Kurzius Lawrence ErikDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000250 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,579 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:35 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000246 · edgar.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,579 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:51 UTC |
Scots-Knight DeniseDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000254 · edgar.xml · nonDerivative · entry 1 Scots-Knight Denise · CIK 0001297000 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,783 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:26 UTC |
BILBREY JOHN PDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000242 · edgar.xml · nonDerivative · entry 1 BILBREY JOHN P · CIK 0001268386 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,783 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:46 UTC |
McDonald Kirk PDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000252 · edgar.xml · nonDerivative · entry 1 McDonald Kirk P · CIK 0001517740 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,783 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:31 UTC |
Harrington Michael JDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000244 · edgar.xml · nonDerivative · entry 1 Harrington Michael J · CIK 0001566340 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,783 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| April 11, 2019 Filed Apr 12, 2019 21:23 UTC |
Anand Kapila KDirector
|
GrantCommon Stock | 2,783 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000240 · edgar.xml · nonDerivative · entry 1 Anand Kapila K · CIK 0001679166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,779 F1 · price: Grant of deferred stock units to each of the non-employee members of the Issuer's Board of Directors, vesting three years from the date of grant. Read SEC document |
| March 13, 2019 Filed Mar 14, 2019 22:16 UTC |
HOOVER R DAVIDDirector
|
PurchaseCommon Stock | 20,000 | $31.43 | $628,586.00 |
DisclosureSEC source: 0000950138-19-000154 · edgar.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Revocable Trust Disclosed balance after: 20,000 F1 · price: The price reported is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $31.38 to $31.50, inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 18:10 UTC |
Schacht Aaron LSee Remarks
|
GrantCommon Stock | 36,424 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000150 · edgar.xml · nonDerivative · entry 1 Schacht Aaron L · CIK 0001752460 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 50,348 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 12, 2019, with 8,836 vesting on December 31, 2019, 14,815 vesting on September 1, 2020, and 12,773 vesting on December 31, 2020. Awards issued in replacement of previously held awards with respect to shares of common stock of Eli Lilly & Company (Lilly), which were forfeited in connection with the completion of an exchange offer on March 11, 2019 by Lilly, in which Lilly disposed of all of Elanco's shares held by it. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 22:06 UTC |
Kinard David SSee Remarks
|
GrantCommon Stock | 34,228 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000148 · edgar.xml · nonDerivative · entry 1 Kinard David S · CIK 0001752439 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 56,797 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 12, 2019, with 16,300 vesting on December 31, 2019 and 17,928 vesting on December 31, 2020. Awards issued in replacement of previously held awards with respect to shares of common stock of Eli Lilly & Company (Lilly), which were forfeited in connection with the completion of an exchange offer on March 11, 2019 by Lilly, in which Lilly disposed of all of Elanco's shares held by it. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 22:13 UTC |
Simmons Jeffrey NDirector · Presiident, CEO & Director
|
GrantCommon Stock | 264,718 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000152 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Presiident, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 394,256 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 12, 2019, with 199,658 vesting on December 31, 2019 and 65,060 vesting on February 1, 2020. Awards issued in replacement of previously held awards with respect to shares of common stock of Eli Lilly & Company (Lilly), which were forfeited in connection with the completion of an exchange offer on March 11, 2019 by Lilly, in which Lilly disposed of all of Elanco's shares held by it. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 18:03 UTC |
LIN SARENA SSee Remarks
|
GrantCommon Stock | 28,698 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000146 · edgar.xml · nonDerivative · entry 1 LIN SARENA S · CIK 0001598788 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 61,813 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 12, 2019, with 14,133 vesting on February 1, 2020 and 14,565 vesting on February 1, 2021. Awards issued in replacement of previously held awards with respect to shares of common stock of Eli Lilly & Company (Lilly), which were forfeited in connection with the completion of an exchange offer on March 11, 2019 by Lilly, in which Lilly disposed of all of Elanco's shares held by it. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 22:00 UTC |
Cabral Ramiro MartinSee Remarks
|
GrantCommon Stock | 20,039 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000144 · edgar.xml · nonDerivative · entry 1 Cabral Ramiro Martin · CIK 0001752437 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 32,780 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 12, 2019, with 8,836 vesting on December 31, 2019 and 11,203 vesting on December 31, 2020. Awards issued in replacement of previously held awards with respect to shares of common stock of Eli Lilly & Company (Lilly), which were forfeited in connection with the completion of an exchange offer on March 11, 2019 by Lilly, in which Lilly disposed of all of Elanco's shares held by it. Read SEC document |
| March 12, 2019 Filed Mar 14, 2019 21:56 UTC |
Urbanek David AlanSee Remarks
|
GrantCommon Stock | 35,433 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000142 · edgar.xml · nonDerivative · entry 1 Urbanek David Alan · CIK 0001752446 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 49,433 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 12, 2019, with 3,144 vesting on December 31, 2019, 9,876 vesting on September 1, 2020, and 22,413 vesting on December 31, 2020. Awards issued in replacement of previously held awards with respect to shares of common stock of Eli Lilly & Company (Lilly), which were forfeited in connection with the completion of an exchange offer on March 11, 2019 by Lilly, in which Lilly disposed of all of Elanco's shares held by it. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 21:59 UTC |
Kinard David SSee Remarks
|
PurchaseCommon Stock | 7,977 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000133 · edgar.xml · nonDerivative · entry 1 Kinard David S · CIK 0001752439 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,569 F1 · price: On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 13,000 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 7,977 shares of Issuer common stock in exchange for 1,768 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 18:02 UTC |
Schacht Aaron LSee Remarks
|
PurchaseCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000135 · edgar.xml · nonDerivative · entry 1 Schacht Aaron L · CIK 0001752460 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 13,924 F1 · price: On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 2,000 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 1,227 shares of Issuer common stock in exchange for 272 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 22:06 UTC |
Simmons Jeffrey NDirector · Presiident, CEO & Director
|
PurchaseCommon Stock | 37,301 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000137 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Presiident, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 129,538 F1 · price: On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 60,800 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 37,301 shares of Issuer common stock in exchange for 8,267 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 21:51 UTC |
HOOVER R DAVIDDirector
|
PurchaseCommon Stock | 920 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000129 · edgar.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Indirect · Suzanne A. Hoover Revocable Trust Disclosed balance after: 920 F1 · price: On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 1,500 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 920 shares of Issuer common stock in exchange for 204 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 22:10 UTC |
Urbanek David AlanSee Remarks
|
PurchaseCommon Stock | 2,021 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000139 · edgar.xml · nonDerivative · entry 1 Urbanek David Alan · CIK 0001752446 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,000 F1 · price: On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 3,294 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 2,021 shares of Issuer common stock in exchange for 448 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted. Read SEC document |
| March 11, 2019 Filed Mar 13, 2019 21:54 UTC |
Cabral Ramiro MartinSee Remarks
|
PurchaseCommon Stock | 1,227 | Not disclosed | Not disclosed |
DisclosureSEC source: 0000950138-19-000131 · edgar.xml · nonDerivative · entry 1 Cabral Ramiro Martin · CIK 0001752437 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,741 F1 · price: On March 11, 2019, Eli Lilly and Company ("Lilly") announced the completion of its offer to exchange shares of Lilly common stock for all of the common stock of the Issuer owned by Lilly (the "Exchange Offer"). The Reporting Person tendered 2,000 shares of Lilly common stock in the Exchange Offer, which shares were subject to a proration factor of 13.5970839%. As a result, the Reporting Person received 1,227 shares of Issuer common stock in exchange for 272 shares of Lilly common stock accepted in the Exchange Offer, based on an exchange ratio of 4.5121 shares of Issuer common stock for each share of Lilly common stock accepted. Read SEC document |
| March 11, 2019 Filed Mar 11, 2019 12:03 UTC |
ELI LILLY & Co10% owner
|
Disposition to issuerCommon Stock | 293,290,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001104659-19-013734 · a4.xml · nonDerivative · entry 1 LILLY ELI & CO · CIK 0000059478 · 10% owner 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · price: Eli Lilly and Company ("Lilly") disposed of 293,290,000 shares of common stock of the Issuer in exchange for 65,000,775 shares of Lilly common stock pursuant to a registered exchange offer to Lilly's common shareholders. The final exchange ratio was 4.5121 shares of Issuer common stock per share of Lilly common stock accepted in the exchange offer. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 18:02 UTC |
Schacht Aaron LSee Remarks
|
GrantCommon Stock | 5,318 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000119 · edgar.xml · nonDerivative · entry 1 Schacht Aaron L · CIK 0001752460 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 12,697 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:53 UTC |
Kinard David SSee Remarks
|
GrantCommon Stock | 5,113 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000113 · edgar.xml · nonDerivative · entry 1 Kinard David S · CIK 0001752439 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,592 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:06 UTC |
Simmons Jeffrey NDirector · Presiident, CEO & Director
|
GrantCommon Stock | 33,950 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000121 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Presiident, CEO & Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 92,237 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:42 UTC |
Hicks Michael-BryantSee Remarks
|
GrantCommon Stock | 8,181 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000110 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 22,906 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 17:56 UTC |
LIN SARENA SSee Remarks
|
GrantCommon Stock | 6,136 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000115 · edgar.xml · nonDerivative · entry 1 LIN SARENA S · CIK 0001598788 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 33,115 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:35 UTC |
Cabral Ramiro MartinSee Remarks
|
GrantCommon Stock | 3,535 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000108 · edgar.xml · nonDerivative · entry 1 Cabral Ramiro Martin · CIK 0001752437 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,514 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:17 UTC |
YOUNG TODD S.See Remarks
|
GrantCommon Stock | 83 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000125 · edgar.xml · nonDerivative · entry 2 YOUNG TODD S. · CIK 0001682584 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,883 F2 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:17 UTC |
YOUNG TODD S.See Remarks
|
GrantCommon Stock | 9,817 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000125 · edgar.xml · nonDerivative · entry 1 YOUNG TODD S. · CIK 0001682584 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,800 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 23:09 UTC |
Urbanek David AlanSee Remarks
|
GrantCommon Stock | 4,500 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000123 · edgar.xml · nonDerivative · entry 1 Urbanek David Alan · CIK 0001752446 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,979 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:59 UTC |
Meer James MChief Accounting Officer
|
GrantCommon Stock | 83 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000117 · edgar.xml · nonDerivative · entry 2 Meer James M · CIK 0001754243 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,237 F2 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, vesting on March 1, 2022. Read SEC document |
| March 01, 2019 Filed Mar 5, 2019 22:59 UTC |
Meer James MChief Accounting Officer
|
GrantCommon Stock | 737 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-19-000117 · edgar.xml · nonDerivative · entry 1 Meer James M · CIK 0001754243 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 5,154 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on March 1, 2019, one-third vesting on March 1, 2020, one-third vesting on March 1, 2021, and the remaining vesting on March 1, 2022. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:10 UTC |
YOUNG TODD S.See Remarks
|
GrantCommon Stock | 8,983 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000651 · edgar.xml · nonDerivative · entry 1 YOUNG TODD S. · CIK 0001682584 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,983 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on December 3, 2018, 50% vesting on December 3, 2019 and remaining 50% on December 3, 2020. Read SEC document |
| December 03, 2018 Filed Dec 6, 2018 21:06 UTC |
Meer James MChief Accounting Officer
|
GrantCommon Stock | 4,192 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000649 · edgar.xml · nonDerivative · entry 1 Meer James M · CIK 0001754243 · Chief Accounting Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 4,417 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on December 3, 2018, 50% vesting on October 1, 2019 and remaining 50% on October 1, 2020. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 22:27 UTC |
Kurzius Lawrence ErikDirector
|
GrantCommon Stock | 1,796 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000644 · edgar.xml · nonDerivative · entry 1 Kurzius Lawrence Erik · CIK 0001352090 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 F1 · price: Grant of deferred stock as an annual equity award to independent members of the Board of Directors. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:16 UTC |
HOOVER R DAVIDDirector
|
GrantCommon Stock | 1,796 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000634 · edgar.xml · nonDerivative · entry 1 HOOVER R DAVID · CIK 0001186033 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 11,796 F1 · price: Grant of deferred stock as an annual equity award to independent members of the Board of Directors. Read SEC document |
| November 30, 2018 Filed Dec 4, 2018 21:30 UTC |
Anand Kapila KDirector
|
GrantCommon Stock | 1,796 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000636 · edgar.xml · nonDerivative · entry 1 Anand Kapila K · CIK 0001679166 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,996 F1 · price: Grant of deferred stock as an annual equity award to independent members of the Board of Directors. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 23:13 UTC |
Kinard David SSee Remarks
|
GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 21,086 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0000950138-18-000572 · edgar.xml · derivative · entry 2 Kinard David S · CIK 0001752439 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,086 Underlying: Elanco Animal Health Inc. Common Stock · 21,086 shares Expires 2028-10-20 F2 · price: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. F2 · derivative.exercise_date: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 23:13 UTC |
Kinard David SSee Remarks
|
GrantCommon Stock | 6,979 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000572 · edgar.xml · nonDerivative · entry 1 Kinard David S · CIK 0001752439 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,479 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 19:30 UTC |
Schacht Aaron LSee Remarks
|
GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 21,086 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0000950138-18-000576 · edgar.xml · derivative · entry 2 Schacht Aaron L · CIK 0001752460 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,086 Underlying: Elanco Animal Health Inc. Common Stock · 21,086 shares Expires 2028-10-20 F2 · price: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. F2 · derivative.exercise_date: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 19:30 UTC |
Schacht Aaron LSee Remarks
|
GrantCommon Stock | 6,979 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000576 · edgar.xml · nonDerivative · entry 1 Schacht Aaron L · CIK 0001752460 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 7,379 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 22:04 UTC |
Simmons Jeffrey NDirector · Pres., Chief Executive Officer
|
GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 109,642 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0000950138-18-000564 · edgar.xml · derivative · entry 2 Simmons Jeffrey N · CIK 0001479079 · Director · Pres., Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 109,642 Underlying: Elanco Animal Health Inc. Common Stock · 109,642 shares Expires 2028-10-20 F2 · price: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. F2 · derivative.exercise_date: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 22:04 UTC |
Simmons Jeffrey NDirector · Pres., Chief Executive Officer
|
GrantCommon Stock | 36,287 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000564 · edgar.xml · nonDerivative · entry 1 Simmons Jeffrey N · CIK 0001479079 · Director · Pres., Chief Executive Officer 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 58,287 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 18:11 UTC |
Hicks Michael-BryantSee Remarks
|
GrantNon-Qualified Stock Option (Right-to-Buy) · Derivative | 29,383 | Not disclosed Strike: $31.61 | Not disclosed |
DisclosureSEC source: 0000950138-18-000566 · edgar.xml · derivative · entry 2 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 29,383 Underlying: Elanco Animal Health Inc. Common Stock · 29,383 shares Expires 2028-10-20 F2 · price: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. F2 · derivative.exercise_date: Grant of stock option pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
| October 20, 2018 Filed Oct 23, 2018 18:11 UTC |
Hicks Michael-BryantSee Remarks
|
GrantCommon Stock | 9,725 | $0.00 | $0.00 |
DisclosureSEC source: 0000950138-18-000566 · edgar.xml · nonDerivative · entry 1 Hicks Michael-Bryant · CIK 0001596081 · See Remarks 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 14,725 F1 · shares: Grant of restricted stock units pursuant to the 2018 Elanco Stock Plan on October 20, 2018, vesting on October 20, 2021. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.